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Abstract
The effects of deuterium-depleted water (DDW) containing deuterium (D) at a concentration of 25 parts per million (ppm),
50 ppm, 105 ppm and the control at 150 ppm were monitored in MIA-PaCa-2 pancreatic cancer cells by the real-time cell
impedance detection xCELLigence method. The data revealed that lower deuterium concentrations corresponded to lower MiA
PaCa-2 growth rate. Nuclear membrane turnover and nucleic acid synthesis rate at different D-concentrations were determined
by targeted [1,2-13C2]-D-glucose fate associations. The data showed severely decreased oxidative pentose cycling, RNA ribose
13C labeling from [1,2-13C2]-D-glucose and nuclear membrane lignoceric (C24:0) acid turnover. Here, we treated advanced
pancreatic cancer patients with DDW as an extra-mitochondrial deuterium-depleting strategy and evaluated overall patient
survival. Eighty-six (36 male and 50 female) pancreatic adenocarcinoma patients were treated with conventional chemotherapy
and natural water (control, 30 patients) or 85 ppm DDW (56 patients), which was gradually decreased to preparations with
65 ppm and 45 ppm deuterium content for each 1 to 3 months treatment period. Patient survival curves were calculated by the
Kaplan-Meier method and Pearson correlation was taken between medial survival time (MST) and DDW treatment in pancreatic
cancer patients. The MST for patients consuming DDW treatment (n¼ 56) was 19.6 months in comparison with the 6.36 months’
MST achieved with chemotherapy alone (n ¼ 30). There was a strong, statistically significant Pearson correlation (r ¼ 0.504,
p < 0.001) between survival time and length and frequency of DDW treatment.
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Introduction
Pancreatic cancer is a rapidly developing disease with poor
prognosis and it is the fourth leading cause of cancer-related
deaths in the Western Hemisphere. Surgical extirpation of
localized disease in a small segment of patients receiving
radiotherapy and concurrent 5-fluorouracil-based chemother-
apy prolongs overall survival to 1.8 years.1 Ninety-five percent
of patients, who are diagnosed at stage III or IV of the disease with
unresectable tumors, expect only an average of 4 to 6 months to
live.2 Patients with unresectable tumors have only a 20% chance
of surviving 1 year following diagnosis and treatment with
single-agent chemotherapy.3 Current major adjuvant treatment
strategies include a second agent, either a cytotoxic or targeted
agent, to gemcitabine, and combined chemoradiotherapy regi-
mens have also been explored to improve overall survival, with
limited success.2 Advanced pancreatic tumors can be reduced into
resectable states by the use of regional chemotherapy that brings
about improvements in overall survival. Approximately 80% of
pancreatic cancer patients have no option for curative resection at
the time of diagnosis.4
A number of biological agents modulating different signal
transduction pathways are currently in clinical development, inhi-
biting angiogenesis and targeting epidermal growth factor recep-
tor, cell cycle, matrix metalloproteinases, cyclooxygenase-2,
mammalian target of rapamycin, or proteasome, but only a few
of them are approved for use in clinical practice with limited
benefit-to-cost ratios.5 Borderline resectable pancreatic carci-
noma has a high risk for margin-positive resection. There is a
consensus that such cancers should be treated with neoadjuvant
chemotherapy and/or chemoradiotherapy before resection. An
extended surgical approach including resection of the superior
mesenteric/portal vein and/or the hepatic artery should be per-
formed when necessary.6 Although margin-negative resection
is achieved in 98% of borderline resectable pancreatic cancer,
survival rate for the patients with borderline resectable disease
was lower than the rate for those with resectable pancreatic
cancer due to a higher incidence of peritoneal and distant
recurrence.7
Restored mitochondrial fumarate hydratase activity has
been shown to eliminate aggressive kidney cancer xenograft
growth8 by switching NADPH production from pentose cycle
back to the mitochondrial matrix.9 The oncogenic
up-regulation of pentose cycle metabolism and NADPH yield-
ing an irreversible oxidative arm10,11 is a well-established
metabolic hallmark of human cancer, as demonstrated by tar-
geted [1,2-13C2]-D-glucose fate associations studies in lung,
12
colon13 and pancreatic cancer.14 The recognition that Gleevec
treatment by restoring mitochondrial fatty acid oxidation
results in profound intracellular metabolic changes that bring
devastating consequences for the survival/proliferation of
leukemia cells of the Bcr-Abl-positive myeloid lineage,15,16
confirm the role of mitochondria in cell cycle regulation.
A novel, submolecular approach to tumor cell physiology
and metabolism can provide explanation to understand the
role of mitochondria in the control of cell division. Two stable
isotopes of hydrogen, protium (H) and deuterium (D) differ in
their physicochemical nature.17-19 Increasing evidence
suggests that D plays a key role in cell proliferation. Consistent
with this, the effect of low deuterium in controlling cell
proliferation is already verified in numerous biological
systems.20-27 The growth rate of tumor cells is significantly
inhibited in culture media prepared with deuterium-depleted
water (DDW), and DDW treatment of mice xenotransplanted
with MDA-MB-231, MCF-7 human breast adenocarcinomas,
or PC-3 human prostate tumors resulted in complete or partial
tumor regression.20,21 The apoptosis-triggering effect of DDW
was demonstrated both in vitro21 and in vivo.22 When labora-
tory animals are exposed to the chemical carcinogen agent
DMBA and expression of c-myc, Ha-ras, and p53 genes are
induced, replacement of drinking water with DDW suppressed
the expression of these genes.28 In addition, DDW significantly
inhibited the proliferation of A549 human lung carcinoma cells
in vitro, while H460 lung tumor xenografts in laboratory mice
showed a 30% growth regression.23 Cancer cells are extremely
sensitive to D-depletion, which can cause tumor necrosis
induced by ROS (reactive oxygen species).17 Recent studies
confirmed that D is a natural cell growth regulator that controls
mitochondrial oxidation-reduction balance.17-19
The anti-cancer effect of D-depletion has already been con-
firmed in a double-blind, randomized, 4-month-long phase II
clinical trial on prostate cancer, and the extended follow-up
suggests that D-depletion readily delays the progression of the
disease.29 D-depletion, in addition to the conventional treat-
ments, improves mean survival time in lung cancer30 even in
an advanced disease, complicated by distant brain metas-
tases.24 In breast cancer patients, DDW treatment in combina-
tion with, or as an extension of, conventional therapies,
significantly improved survival in advanced disease and was
also effective in the prevention of recurrences in early-stage
breast cancer.31
Herein we report that D-depletion in water alone inhibits
MIA PaCa-2 pancreatic cancer cell growth in vitro by control-
ling NADPH-dependent reductive synthesis via the oxidative
pentose cycle and that the decrease of serum deuterium after
the consumption of DDW in addition to conventional therapies
offers a 3-fold extension in MST in patients with advanced
pancreatic cancer.
Materials and Methods
Production of Deuterium-Depleted Water (DDW)
DDW containing Deuterium (D) at concentrations of 25 parts
per million (ppm)31 is fractionated based on the different vola-
tility of HDO and D2O compared to light water (H2O), which
has 150 ppm D in HDO and D2O form (heavy water). The
proper D-concentration for different experiments was prepared
by mixing DDW with 25 ppm D-concentration with distillated
water of 150 ppm D-concentration. At the boiling point of
normal water, the steam in equilibrium with the liquid phase
contains approximately 2.5% less DHO (semi-deuterated
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water). Industrial quantities of DDW is obtained by repeating
evaporation steps in vacuumed distillation towers and by
European Standards the deuterium content of water is
decreased commensurate with the tray number of the distilla-
tion tower. For the current study, D-concentration in culture
media, drinking water and venous blood serum were deter-
mined by mass spectrometry (Finnigan delta plus XP, using
BTW XV standards) with +1 ppm precision and reported in
reference to the Vienna standard of mean oceanic water
(<150 ppm).32,33 Repeated blood D-concentration measure-
ments were also performed in serum and correlated with daily
deuterium intake (including drinking water and food) of
40 ppm, 65 ppm and 100 ppm water. The Michaelis–Menten
kinetics of serum and interstitial water pool deuterium satura-
tion and exchange in response to decreasing deuterium intake
in water by a patient volunteer was determined.
Culture Media and Cell Lines
Media with increasing D-concentrations were prepared using
6.68 g DMEM (1000 ml stock powder; Gibco BRL, Carlsbad,
CA, USA), containing penicillin (50 IU/ml), streptomycin
(50 mg/ml), 10% fetal bovine serum (FBS) and 2% horse
serum. The final volume of DDW preparations was allocated
as fractions in distilled water containing D at a concentration of
150 ppm, by mixing (vol/vol) with the DDW stock containing
D at a concentration of 24 ppm. Culture media were filtered
using Acrodisc Premium 25 mm syringe filters with 0.2 mm
GHP membrane (Pall Life Sciences, NH, USA). The 2-stock
media, i.e.: 24 ppm and 150 ppm D, were mixed to yield 50 ppm
and 105 ppm D-concentration for the dose-dependent prolifera-
tion studies. Cells were starved with FBS depletion overnight.
For real-time cell adhesion assay, MIA PaCa-2 cells were
seeded at a density of 11000 cells per well into 96-well
E-plates and maintained in a humidified atmosphere cell cul-
ture cabinet with 95% filtered air and 5% CO2.
Real-Time Cellular Impedance Analysis Using the
xCELLigence System
Cell growth was monitored with the real-time electronic impe-
dance sensing xCELLigence System (RT-CES, Acea-Roche,
Basel, Switzerland).34 Cytotoxic effects of DDW containing
D at a concentration of 25 ppm, 50 ppm, 105 ppm and the
control (150 ppm) as single treatments or in combination with
cisplatin (Selleckchem, Avidin Ltd, Hungary, Szeged) at a
concentration of 20 mM, 40 mM or 60 mM were tested in MIA
PaCa-2 (CRL-142, American Type Culture Collection—
ATCC) human pancreatic carcinoma cells. Cisplatin was
freshly diluted in a concentration of D matching DMEM cul-
ture media. The cells were given the freshly prepared cisplatin
and volume equivalent media prepared with DDW at the same
time as DDW control cultures. The RT-CES 96-well E-plate
was coated with gelatin and then washed twice with PBS.
Growth media were then gently dispensed into each well of
the 96-well E-plate for background readings by the RT-CES
system prior to addition of cell suspension at a density of
11000 cells in each well. Impedance reading plate holding
devices containing the cell suspension were kept at 37 oC in
a CO2 incubator overnight prior to treatment with DDW and/or
cisplatin. Cell growth was monitored for 72 h by recording
electrical impedance every 5 minutes. The dimensionless para-
meter termed Cell Index (CI) was derived as relative change in
measured electrical impedance of DDW cultures relative to the
control 150 ppm impedance, which reflects viability of treated
cells as well as their count, respectively.
Targeted [1,2-13C2]-D-Glucose Fate Association Study
All reagents were purchased from Sigma-Aldrich (St. Louis,
MO) unless otherwise stated. All experiments were conducted
in triplicate. Twenty-four hours prior to DDW treatment and
metabolomics study, 2 x 106 MIA-PACA, H449 or MCF-7
positive control cells were grown in T-75 cm2 culture
flasks with glucose and sodium pyruvate-free DMEM
containing 10% FBS, 1% penicillin /streptomycin, 180 mg/dL,
of which 50% of total final glucose was derived from the
[1,2-13C2]-D-glucose tracer (Isotec, Miamisburg, OH). The tra-
cer was added to the media for all cells for 72 hours. Media and
trypsinized cell lysates were collected and frozen at -80C until
analysis.
Product Extraction and Derivatization
Extraction and derivatization procedures for glucose, choles-
terol, fatty acids, lactate, CO2 and glutamate were previously
published for targeted tracer fate association matrices.35 Sterols
and fatty acids were extracted by saponification of Trizol
(500 mL, Invitrogen, Carlsbad, CA) cell extract after removal
of the upper glycogen- and RNA-containing supernatant using
30% KOH and 70% ethanol (300 ml each) for 2 hours.36 Sterol
extraction was performed using 5 mL petroleum ether (EMD,
Gibbstown, NJ) with repeated shaking for 20 seconds 3 times.
The molecular ion of cholesterol was monitored at the m/z
386 ion cluster. Fatty acids were extracted by further acidifica-
tion using 6 N hydrochloric acid to pH below 2.0 and repeated
vortexing with 5 mL petroleum ether. Fatty acids
(methyl-palmitate; C16:0) were monitored at m/z 270 using
canola oil as positive control and methyl-lignocerate (C24:0)
was monitored at m/z382. The enrichment of acetyl units in
media and cell pellet palmitate in response to 100 ppm, 50 ppm
and 25 ppm DDW treatments was determined using the mass
isotopomer distribution analysis (MIDA) approach. Acetyl-
CoA and fractions of new synthesis were calculated from the
m4/m2 ratio using the formula m4/m2¼ (n-1)/2(p/q), where n
is the number of acetyl units, p is the 13C-labeled precursor
acetate fraction and q is the 12C-labeled natural acetate fraction
(pþq ¼ 1).37,38
For glucose extraction, 500 mL each of 0.3 N barium hydro-
xide and 0.3 N zinc sulfate were added to 100 mL media.
Samples were vortexed and centrifuged for 15 min at
10,000 rpm. Supernatant was dried on air overheat and were
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derivatized by adding 150 mL hydroxylamine solution and
incubated for 2 h at 100C followed by addition of 100 mL of
acetic anhydride. Samples were incubated at 100C for 1 h and
dried under nitrogen overheat as previously described in the
fatty acid derivatization section. Ethyl acetate (200 mL) was
added. Peak glucose ion was detected at m/z 187 cluster.
Lactate was extracted from media through acidification of
100 mL media with HCl and addition of 1 mL of ethyl acetate.
The resulting aqueous layer was dried under nitrogen overheat
and derivatized using lactate standard solution as positive con-
trol. 200 mL of 2,2-dimethoxypropane was added followed by
50 mL of 0.5 N methanolic HCl. Samples were incubated at
75C for an hour. 60 mL of n-propylamine was added and
samples were heated for 100C for an hour followed by addi-
tion of 200 mL dichloromethane. Heptafluorobutyric anhydride
(15 mL) was added followed by 150 mL of dichloromethane and
samples were subjected to GC/MS. M1 and m2 lactate were
differentiated to distinguish the pentose phosphate flux from
anaerobic glycolysis and the ion cluster at m/z 327 (electron
impact ionization) was examined.39
13CO2 Assay for CO2 was generated by adding equal
volumes (50 mL) of 0.1 N NaHCO3 and 1 N HCl to spent media
and 12CO2/
13CO2 ion currents were monitored and calculated
from the m/z44 and m/z45 peak intensities, respectively, using
13CO2/
13CO2 of cell culture cabinet’s CO2 tank as the reference
ratio for 13CO2 calculations.
Gas Chromatography/Mass Spectrometry
Agilent 5975 Inert XL Mass Selective Detector connected to
HP6890 N Network gas chromatograph was used to detect
mass spectral data under the following settings: GC inlet
230C, MS source 230C, MS Quad 150C.40 For media
CO2, glucose and lactate analyses, an HP-5 column (30 m
length x 250 mm diameter x 0.25 mm thickness) was used while
a DB-23 column (60 m length, 250 mm diameter x 0.15 mm
thickness) was used for fatty acid measurements.
Statistics
Mass spectral analyses were obtained by consecutive and inde-
pendent injections of 1 mL sample using an autosampler with
optimal split ratios for column loading (106 > abundance > 104
abundance). Ion currents were accepted for spectra processing
if the standard sample deviation was below 5% of the normal-
ized peak intensity (integrated peak area of ion currents; 100%)
among repeated injections. Data download was performed in
triplicate manual peak integrations using modified (back-
ground subtracted) spectra under the overlapping isotopomer
peaks of the total ion chromatogram (TIC) window displayed
by the Chemstation (Agilent, Palo Alto, CA) software by
spectral chemistry technicians, who were blinded to sample
identities, blanks and natural 13C abundance internal standard
study samples. A 2-tailed independent sample t-test was used to
test for significance (p<0.05, p<0.01) between control
(150 ppm DDW) and the treated groups (100 ppm, 50 ppm and
25 ppm D for DDW responsive metabolic flux surrogates.
Clinical Study Design and Eligibility Criteria
A total of 86 (36 males and 50 females) patients with histolo-
gically confirmed pancreatic carcinoma were continually
enrolled (DDW group ¼ 56, control group ¼ 30) from March
1995 to January 2020. Two of these patients, 1 female and
1 male were operated before entering the study, the other
patients were inoperable. Patients were evaluated on approved
EU compliant Institutional Review Board (IRB) protocol
(Clinical Trials Identifier: HYDPACA1995-2020 for this
report; Principal Investigator: Somlyai G. PhD) and for surgi-
cally evaluated 150 ppm DDW controls (SZOTE; Principal
Investigator: Farkas jr. Gy. MD, PhD). Regarding the length
of DDW treatment, patients who continued taking DDW for at
least 91 days were eligible. Fifty-six (22 males and 34 females)
patients met the inclusion criteria of this report in the DDW
group, and their clinical progression was retrospectively evalu-
ated. For the DDW group daily water intake of all patients was
replaced with DDW, which was integrated in the conventional
treatment regimens, as patients were administered DDW orally,
ad libitum, in addition to the conventional treatment regimen.
These patients were continuously updated with, aware of, and
provided access to all available information and publications
regarding the DDW treatment that they consented to. DDW
treatment started with 85 ppm D, which was gradually (every
1-3 months) decreased to preparations with 65 ppm and 45 ppm
for 30 to 90 days (1 to 3 months). The endpoint of the study was
overall survival based on vital statistics. We used Kaplan-Meier
survival estimates. Explanatory variable was the time from diag-
nosis to end to follow-up in months. Outcome variable was
death. For correlation analysis, the Pearson method was used.
Variables were DDW treatment in days and survival time in
days. The calculations were performed by AdwareResearch
Partner.
Disease Characteristics in the 56 DDW-Treated
Pancreatic Cancer Patients
Patients had already been diagnosed with advanced stage IV
pancreatic cancer before they entered the DDW study.
26 patients had metastatic pancreatic cancer. Different types
of metastases were detected in 18 patients (69.2%), mostly in
the liver. All patients underwent conventional treatments with
chemotherapeutic agents except one 69-year-old female
patient. The majority of patients were treated with standard
intravenous gemcitabine, which was combined with
5-fluorouracil in 4 cases. Cisplatin was used as the primary
chemotherapeutic drug in 3 patients.
The median age of the 56 DDW-treated patients was
62.0 years. Median duration of the treatment with DDW was
7.3 months (85 ppm, 65 ppm and 45 ppm regimen (DDW).
The treatment period showed a high standard deviation
(SD: 8.18 months), because 12 patients (21%) consumed DDW
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for an extended period, more than 1 year, upon clinical
improvement, with the longest treatment periods reaching up
to 1.2 and 3.2 years. Follow-up period from the diagnosis (DG
to Flwup) was also longer in comparison with other clinical
reports on advanced pancreatic cancer, DG_to_Flwup was
13.1 months (SD: 22.2 months). Patients started the DDW
treatment at different time points at their consent after the
diagnosis, which was recorded, and the median lengths
between diagnosis and entering the trial (DG_to_DDWstart)
was 1.7 months (SD: 12.2 months). When data sheets were
closed in order to meet study deadline objectives (January
2020) for standard matrix diagnostics, data processing and
abstracting, 31 patients were still alive (L/E ¼ 31/25) and were
offered continued DDW treatment. Therefore these patients are
included in this report with at least their applicable (at least)
mean survival time upon study termination (Table 1).
Disease Characteristics in the 30 Control Pancreatic
Cancer Patients Ingesting Normal Water (150 ppm)
The median age of the 30 control, natural deuterium-containing
water-consuming patients was 65.9 years (SD ¼ 9.05 years)
(Female: n ¼ 16, Average age: 67 years, SD ¼ 9.24 years;
Male: n ¼ 14, Average age: 64.3 years, SD ¼ 8.9). When
control patients were explored for potential surgical resection,
disseminated diseases with liver and lymph node metastases
were observed and multiple lymph node biopsies were obtained
without additional surgical intervention. Histology in all cases
confirmed pancreatic adenocarcinoma and all patients received
standard treatment with gemcitabine (Gemzar 1000 mg/m2 as
an intravenous infusion) combined with 5-fluorouracil consis-
tent with the EU gastrointestinal adenocarcinoma disease
management protocol.
Results
In vitro growth inhibition by deuterium-depleted water (DDW)
alone or in combination with cisplatin in MIA PaCa-2 pancreatic
cancer cells
Table 1. Descriptive Statistics of the 56 DDW Treated Patients With Pancreatic Cancer.
Variable Median Mean Standard deviation of mean Cumulative time
DG_to_DDWstart 1.7 months 6.1 months 12.2 months 27.9 years
Low DDW 7.3 months 10.2 months 8.18 months 47.1 years
DG_to_Flwup 13.1 months 20.7 months 22.2 months 95.3 years
DDWstart_to_Flwup 8.4 months 14.6 months 17.1 months 67.4 years
L/E ¼ 31/25.
Figure 1. Targeted [1,2-13C2]-D-glucose fate associations show
decreased RNA ribose turnover in Mia-PaCa cells after DDW
treatment, whereby the more differentiated H441 (lung) and MCF-7
(breast) cells showed no response in ribose 13C turnover in this
72 hours 13C labeling study. (n ¼ 3; þSD).
Figure 2. Targeted [1,2-13C2]-D-glucose fate associations show
decreased limited nuclear membrane fatty acid lignocerate (C24:0)
synthesis and palmitate (C16:0) synthesis in MIA-PaCa cells.
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Targeted [1,2-13C2]-D-Glucose Fate Associations
Targeted [1,2-13C2]-D-glucose fate associations indicated that
new RNA ribose synthesis and turnover decreased in Mia-PaCa
cells after DDW treatment (Figure 1), which was associated
with limited nuclear membrane fatty acid lignocerate (C24:0)
and palmitate (C16:0) syntheses. MCF-7 breast cancer cells
also showed a metabolic response, whereby nuclear membrane
cholesterol synthesis was decreased (Figure 2).
Culture media [3-13C1]-DL-lactate and [2,3-
13C2]-DL-lac-
tate ratios, produced from the [1,2-13C2]-D-glucose tracer via
the oxidative branch of the pentose cycle in the expense of the
hexose phase of the glycolytic flux showed a significant
decrease in glucose-6-P dehydrogenase (G6PDH) flux and
NADPH production from the 5.45 (n ¼ 3; SD ¼ 0.17) control
value to 4.75 (n ¼ 3; SD ¼ 0.16) 100 ppm DDW, 4.75 (n ¼ 3;
SD¼ 0.22) 50 ppm DDW and 4.82 (n¼ 3; SD ¼ 0.19) 25 ppm
DDW treatment, respectively.
Cell Growth Inhibitory Effect
The cell growth inhibitory effect of D-depletion on the MIA
PaCa-2 pancreatic cancer cell line was investigated using the
real time, non-label system of xCELLigence RTCA. Cells were
treated with DDW containing deuterium at a concentration of
25 ppm, 50 ppm or 105 ppm and the impedance Cell Index (CI)
was plotted for each treatment. Control measurement was car-
ried out by adding D to cells at the natural concentration of 150
ppm. Lower D-concentrations showed dose-dependent
decrease in CI compared to water containing D at 150 ppm
(Figure 3).
The growth inhibitory effect of DDW was confirmed by the
fact that MIA PaCa-2 cells are resistant to gemcitabine and
consistent with this, the combined treatment with gemcitabine
(60 mM) and DDW did not result in further inhibition of pre-
viously observed cell growth or cell viability achieved with
DDW. In other words, CI values did not differ significantly
from the values that were measured with decreasing deuterium
concentrations without gemcitabine as shown in Figure 3.
Cytostatic Effect
The cytostatic effect of 20 mM, 40 mM or 60 mM cisplatin in
MIA Paca-2 cells was evident by the dose-dependent decrease
of CI values during the real-time cell impedance test using D at
the 50 ppm (Figure 4a). Treatment with 20 mM cisplatin in
cell medium containing 50 ppm and 25 ppm D resulted in
significantly lower CI values at 24hs than that with 150 ppm
or 50 ppm DDW alone (Figure 4b).
Figure 3. (a) Decreased cell impedance and count (Cell Index) after treatment with low concentrations of D (25 ppm, 50 ppm or 105 ppm) in
MIA PaCa-2 pancreatic cancer cells in a growth curve after priming for 24 hours, then allowing to propagate up to 55 hours. (b) MIA-PACA-2
viability after 24 hours of DDW treatment in comparison with control cultures as indicated on the Y-axis. Natural D concentration (150 ppm)




Regression statistics between average daily DDW-intake
(including drinking water and food) for several weeks or
months and serum D-concentrations (n¼ 10; Figure 5) showed
a y¼ 0.9873xþ27.177 slope and intercept with a very high >0.8
(R2 ¼ 0.8497) positive correlation coefficient between dietary
deuterium content (degree of deuterium-depletion) and that of
serum.
Michaelis–Menten kinetics of serum and interstitial water
pool saturation and exchange in response to lowered D-intake
of 10 different cancer patient volunteers showed the equilibrium
concentration after DDW-consumption. The data on Figure 5
show deuterium (precursor enrichment) in serum and interstitial
fluid via deuterium exchange after a period of time of any given
DDW sample consumption as shown on the X-axis.
Pearson correlation was measured between survival times
and DDW treatment in pancreatic cancer patients (Figure 6).
We found a strong, statistically significant correlation between
survival time and length of DDW treatment. (r ¼ 0.504,
p < 0.001).
DDW Consumption Increases MST
Calculations of the MST by the 56 DDW-
Consuming Patients
Deuterium depletion increased MST in all 56 patients who, in
addition to the conventional cytostatic treatments for pancrea-
tic cancer, also underwent treatment with DDW. The MST
from diagnosis (Figure 7) was on average 19.6 months in the
DDW-treated cohort.
The MST in the control group with 30 patients was
6.88 months in females (n ¼ 16; SD ¼ 2.52) and 5.86 months
in males (n ¼ 14; SD ¼ 2.03).
Calculations of the MST Using Different Parameters,
Cohort by Gender, Metastasis, Age and Weight
The MST was 21.467 months (95% CI: 12.031-30.902) in the
female subgroup (n ¼ 34) and 15.167 (95% CI: 7.824-22.509)
in the male subgroup (n ¼ 22).
Figure 4. (a) Cisplatin at 20 mM, 40 mM and 60 mM concentration, for 24 h inhibited cell viability of MIA PaCa-2 pancreatic cells
dose-dependently, compared to CI values measured after treatment with 50 ppm D-concentration. (n ¼ 3 þSD; *p < 0.05 in DDW treated
cultures in comparison with 150 ppm and 50 ppm of D; #p < 0.05 in DDW treated cultures in comparison with 20 mM cisplatin). (b) Cisplatin at
20 mM concentration for 24 h inhibited cell viability of MIA PaCa-2 pancreatic cells dose-dependently after treatment with 105 ppm, 50 ppm and
25 ppm of D, compared to CI values to control (150 ppm þ 20 mM cisplatin) (n ¼ 3 þSD; *p < 0.05 in DDW and cisplatin-treated cultures in
comparison with 150 ppm and 20 mM cisplatin-treated culture)
Figure 5. Scatterplot of daily DDW-intake (including drinking water
and food) for several weeks or months and serum D-concentrations.
Slope and intercept: y ¼ 0.9873xþ27.17 . (n ¼ 10; R2 ¼ 0.85).
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The MST was 19.600 months (95% CI: 10.241-28.959) in
patients with no metastasis (n ¼ 30) and 19.400 (95% CI:
10.281-28.519) in patients with metastasis (n ¼ 26).
The MST was 25.700 months (95% CI: 9.612-41.788) in
patients younger than 60 years (n ¼ 23) and 18.433 (95% CI:
14.187-22.680) in patients older than 60 years (n ¼ 33).
The MST was 21.467 months (95% CI: 11.955-30.978) in
patients weighing under 70 kgs (n ¼ 33) and 17.233 (95% CI:
11.431-23.035) in patients weighing 70 kgs or more (n ¼ 23).
Although the differences between the subgroups were not
statistically significant, in the comparable subgroups we drew
the inference that the changes in MST were very remarkable.
The difference was not so large in 1 case, between those
patients who had and who not had metastasis.
Calculations of the MST With Statistically
Significant Parameters in 56 Pancreatic Cancer
Patients Cohort by the Number of Cures
The MST was 17.233 months (95% CI: 12.494-21.973) in
patients with only 1 DDW-cure (n ¼ 44). MST could not be
determined for patients with more than 1 DDW-cure (n ¼ 12),
the mean survival time was 71.911 months (Figure 8). The
difference between the 2 subgroups was statistically significant
(p ¼ 0.010).
Discussion
Gastrointestinal tract adenocarcinoma malignancies, which are
the most common type of pancreatic cancers, are progressive in
their clinical appearance. They are often diagnosed at a late
stage with severely compromised expectancy and quality of life
due to the many serious complications, besides their rapid
course. Recent reviews regarding surgical41 management and
Figure 6. Pearson correlation between survival time in days and DDW treatment in days for 56 pancreatic cancer patients.
Figure 7. Calculation of MST in 56 pancreatic cancer patient cohort
(95% CI: 14.252-24.948).
Figure 8. MST in the 56 pancreatic cancer patient cohort calculated
using the number of cures.
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experimental42 approaches to address molecular mechanisms
admit the lingering of new challenges regarding recurrence,
resistance and aggressive/invasive cellular phenotypes. For this
report we limited deuterium load via oncogenic NAD(P)H
synthesis by the oxidative arm of the pentose cycle, nuclear
membrane fatty acid chain elongation and nucleic acid ribose
turnover by DDW, which mimic metabolic profiles obtained
after Glivec10 treatment in myeloid leukemia, or after choles-
terol and metformin treatment in in vivo grown pancreatic can-
cer (Figure 9).36,43
This work provides a distinct clinical translational proof that
providing an extracellular deuterium-depleted water source for
tumor cells during defective ketogenic substrate oxidation in
the mitochondrial matrix, a process that is being diminished in
tumor cells to deplete heavy hydrogen (deuterium) on their
own via metabolic water production and recycling, is an effi-
cient integrative therapeutic approach to potentially treat such
cancers in the future. Such principle via deuterium-depleting
(deupleting) metabolic markers has clinically been shown in
several independent original contributions involving lung,44
rare childhood,45 renal cell46 and colorectal cancers47 with only
lacking evidence until now in prostate cancer. The underlying
precise medical biochemistry related mechanism of how defec-
tive mitochondria with consequentially diminished low deuter-
ium ketogenic fatty acid substrate oxidation and thus hampered
recycling of deuterium-depleted (deupleted) metabolic water
via TCA cycle hydratase reactions is described elsewhere and
herein provided for further reading.27,48 Such review of the
pertinent literature better positions our results within the grow-
ing state of deutenomics art that consistently shows the
increased significance of deuterium depletion via natural cel-
lular ketogenic substrate oxidation to preserve normal differ-
entiated cellular phenotype in the above cancers to prevent,
reverse or cease cancer formation.
We demonstrated the additive anti-growth inhibitory effects
of D-depletion in combination with cisplatin in pancreatic can-
cer cells, in vitro. This is a clear indication that the application
of DDW in combination with chemotherapy allows the reduc-
tion of chemotherapeutic drug dosing, while keeping similar
efficacies. This observation suggests that DDW treatment may
possibly attenuate devastating side effects of anticancer drugs
at lower, but clinical still efficacious concentrations.
This study recruited and enrolled advanced, pancreatic
cancer cases with homogenous surgical staging that reflect an
Figure 9. Comparison of metabolic profile changes associated with A) deuterium depletion or B) Glivec in leukemia and Metformin (MET) in
Mia-PaCa cells. In normal cells natural deuterium depletion occurs via mitochondria-dependent NAD(P)H production, a process compromised
in all cancer cells. Glivec restores and Metformin improves mitochondrial fatty acid substrate oxidation with TCA cycle turnover and increase
fumarate hydratase, hence low deuterium-containing metabolic water recycling for NAD(P)H-driven reductive macromolecule synthesis of the
normal mammalian cell. Glivec and Metformin treatment also strongly inhibit the oxidative deuterium loading arm of the pentose cycle from free
water (panel B). Deuterium depletion in free (drinking) water and the serum of pancreatic cancer patients mimic restored mitochondrial
deuterium depletion for reductive synthesis via limiting deuterium load through oncogenic NAD(P)D production in the oxidative arm of the
pentose cycle (panel A), regardless of compromised mitochondrial activity thus “tricking” tumor cells.
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advanced late disease. This group of patients has the most
limited life expectancy among all cancers, not only that of the
pancreas. The study population consisted of 56 patients; whom
all, except one 69-year-old woman, underwent chemotherapeu-
tic disease management according to conventional regimens
used in the EU. Here we report 19.6 months medial MST from
diagnosis. These are markedly longer survivals than what retro-
spective clinical data reveal for advance pancreatic cancer
patient life expectancy.49,50 This observation suggests that
D-depletion in addition to conventional treatments prolongs
survival at an advanced stage more efficiently than any targeted
or combined therapy achieved, to date. The one 69-year-old
female patient, who elected not to have chemotherapy but deu-
terium depletion alone, regardless of her advanced disease
complicated with a large tumor confined to the head of the
pancreas causing obstructive jaundice, liver metastases and dia-
betes during the follow-up period, still took DDW for 441 days
(14.46 months). This data suggests that pharmacological
D-depletion below 85 ppm D, followed by further depletion steps
to 65 ppm and 45 ppm, respectively, may offer significant delays
in disease progression with well-maintained routine daily activi-
ties, similar to what is observed in Glivec-treated leukemia
patients with similar metabolic targets and mechanisms to control
disease progression.
In addition, D-depletion in water or food has exceptionally
favorable toxicity profiles by being harmless, and therefore
DDW can safely be used according to preclinical and clinical
safety evaluations obtained in this study. Patients at advanced,
medically complicated disease stages can still be offered
DDW, which can readily be integrated into chemotherapy
treatment regimens with the clear benefit of controlling epige-
netic deuterium loading into DNA and nuclear membrane fatty
acids, thus increasing nuclear stability as DDW’s primary
anticancer property through all extra-mitochondrial NAD(P)H
synthesis pathways; particularly that of the direct glucose oxi-
dizing arm of the pentose phosphate pathways, cytoplasmic
fumarate hydratase and the serine oxidation glycine cleavage
reactions of oncogenic NAD(P)H producing glycolysis with an
alternate Warburg effect.51
The Median survival time for patients consuming DDW
treatment (n ¼ 56) was 19.6 months in comparison with the
6.36 months MST achieved with chemotherapy alone (n¼ 30).
MST calculations in different subgroups of 56 patients were
taken. Different important records were thoroughly investi-
gated for possible parameters that might influence the outcome,
and the subgroup evaluation was performed based on these
aspects.
By parameters of metastasis and age (cut-off: 60 years), we
detected differences between the groups. MST was higher in
those patients, who had no metastasis compared to patients
with metastasis. Furthermore, a big difference was observed
in the MST of the age parameter subgroup. MST was much
higher in those patients, who were younger than 60 years, com-
pared to patients older than 60 years.
We detected an even bigger difference by gender and weight
(cut-off: 70 kgs). MST was significantly higher in the female
subgroup, compared to the male subgroup. Furthermore, MST
was much higher in patients weighing less than 70 kgs compared
to patients weighing more than 70 kgs. Comparing the groups of
gender and weight status (Table 2), we could detect a correlation.
Men on average weigh more than women and the lower
bodyweight may result in higher DdU in women with the same
DDW-intake. This fact also suggests that DdU can be a deter-
minative factor influencing MST.
The other key issue determining the effectiveness of
D-depletion was the frequency of DDW applications (single
or repeated treatment). Although single DDW treatment
extended survival in comparison with published MSTs,
repeated DDW treatments resulted in outstandingly long sur-
vival times. Patients who took DDW for only 1 treatment
period (n¼44) had an MST of 17.23 months, whereas patients
(n ¼ 12) who took DDW-cures more than once had a mean
survival time of 71.91 months.
These results strongly suggest that DDW treatment provided
additional benefits to pancreatic cancer patients and had a sig-
nificant role in delaying progression. Most importantly these
findings are in close correlation with the importance of deuter-
ium-depleted metabolic water production via metabolic and
nutritional ketosis in the mitochondria of differentiated cells
both for the radiological diagnosis and treatment of human
cancers.52
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